Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members — Chicago, Illinois, December 2020–March 2021

Richard A. Teran¹,²,* | Kelly A. Walblay²* | Elizabeth L. Shane² | Shannon Xydis² | Stephanie Gretsch³ | Alexandra Gagner² | Usha Samala² | Hyeree Choi² | Christy Zelinski² | Stephanie R. Black²

¹Epidemic Intelligence Service, CDC, Atlanta, Georgia
²Chicago Department of Public Health, Communicable Disease Program, Chicago, Illinois
³Chicago Department of Public Health, Immunization Program, Chicago, Illinois

Correspondence
Richard A. Teran, Epidemic Intelligence Service, CDC, Atlanta, GA, USA
Email: rteran@cdc.gov

Early studies suggest that COVID-19 vaccines protect against severe illness;¹ however, postvaccination SARS-CoV-2 infections (i.e., breakthrough infections) can occur because COVID-19 vaccines do not offer 100% protection.²,³ Data evaluating the occurrence of breakthrough infections and impact of vaccination in decreasing transmission in congregate settings are limited. Skilled nursing facility (SNF) residents and staff members have been disproportionately affected by SARS-CoV-2, the virus that causes COVID-19,⁴,⁵ and were prioritized for COVID-19 vaccination.⁶,⁷ Starting December 28, 2020, all 78 Chicago-based SNFs began COVID-19 vaccination clinics over several weeks through the federal Pharmacy Partnership for Long-Term Care Program (PPP).† In February 2021, through routine screening, the Chicago Department of Public Health (CDPH) identified a SARS-CoV-2 infection in a SNF resident >14 days after receipt of the second dose of a two-dose COVID-19 vaccination series. SARS-CoV-2 cases, vaccination status, and possible vaccine breakthrough infections were identified by matching facility reports with state case and vaccination registries. Among 627 persons with SARS-CoV-2 infection across 75 SNFs since vaccination clinics began, 22 SARS-CoV-2 infections were identified among 12 residents and 10 staff members across 15 facilities ≥14 days after receiving their second vaccine dose (i.e., breakthrough infections in fully vaccinated persons). Nearly two-thirds (14 of 22; 64%) of persons with breakthrough infections were asymptomatic; two residents were hospitalized because of COVID-19, and one died. No facility-associated secondary transmission occurred. Although few SARS-CoV-2 infections in fully vaccinated persons were observed, these cases demonstrate the need for SNFs to follow recommended routine infection prevention and control practices and promote high vaccination coverage among SNF residents and staff members.

CDPH monitors SNF SARS-CoV-2 infections using a data triangulation method that matches the SARS-CoV-2 test results from nucleic acid amplification tests (NAATs, such as reverse transcription–polymerase chain reaction [RT-PCR]) and antigen tests reported to the Illinois’ National Electronic Disease Surveillance System with facility-reported line lists of SARS-CoV-2 test results from routine screening testing.§ In February 2021, CDPH began matching records to Illinois’ Comprehensive Automated Immunization Registry Exchange to identify breakthrough infections. After identifying SARS-CoV-2 infection in a SNF resident 16 days after receipt of a second vaccine dose, CDPH initiated an investigation to quantify breakthrough infections across all facilities, evaluate symptoms and clinical outcomes, and assess potential secondary transmission. Vaccine effectiveness was not evaluated.

A facility’s investigation period started on its first vaccination clinic date and ended March 31, 2021.² A confirmed case of SARS-CoV-2 infection was defined as a positive SARS-CoV-2 NAAT or antigen test result from a respiratory specimen collected from a resident or staff member during the investigation period. Consistent with CDC guidance, a vaccine breakthrough infection in a resident...
or staff member was defined as a receipt of a positive SARS-CoV-2 NAAT or antigen test result from a respiratory specimen collected ≥14 days after completing the two-dose COVID-19 vaccination series. Infection prevention specialists conducted case investigations to assess symptoms, clinical outcomes, and close contact information.

SARS-CoV-2 incidence during the investigation period was assessed across four groups based on vaccination status at the time a positive respiratory specimen was collected: (1) unvaccinated (never received a COVID-19 vaccine dose); (2) partially vaccinated (received one dose of a two-dose series); (3) vaccinated but not immune (received two doses of a two-dose series but <14 days had elapsed since the second dose); and (4) fully vaccinated (received two doses of a two-dose series and ≥14 days had elapsed since the second dose). In addition to routine facility follow-up, CDPH actively monitored facilities with breakthrough infections for 28 days to identify whether any new cases occurred in close contacts of the person with breakthrough infection. Analyses were completed using SAS (version 9.4; SAS Institute). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.

During the investigation period, an estimated 7931 SNF residents and 6834 staff members received two doses of COVID-19 vaccine. A total of 627 confirmed SARS-CoV-2 infections were identified across 75 of the 78 Chicago-based SNFs, including 353 (56%) among residents and 274 (44%) among staff members during the investigation period (Table 1). Three facilities had no confirmed SARS-CoV-2 infections after their first vaccination clinic. Approximately one half (47%) of resident cases occurred in men, 42% were in non-Hispanic Black persons, and the median age was 71 years. More than two-thirds (72%) of staff member cases were in women, 38% were in non-Hispanic Black persons, and the median age was 42 years. Among the 627 cases, 447 (71%) occurred in unvaccinated persons, 145 (23%) in partially vaccinated persons, 13 (2%) in vaccinated but not immune persons, and 22 (4%) in fully vaccinated persons (Figure 1). These breakthrough infections occurred in 12 residents and 10 staff members and accounted for 16% (22 of 136) of SNF-associated cases occurring across all facilities ≥14 days after the second vaccination clinic at the respective facilities. No demographic or clinical differences were observed by vaccination status.

Among the 22 breakthrough infections, 18 (82%) were detected in persons who received testing as part of routine screening, and four (18%) occurred in residents who received testing before a hospital admission or procedure. Among the 18 breakthrough infections identified during routine screening, 14 were detected (across 10 facilities) while residents were receiving weekly testing from the facilities; staff members at all facilities were receiving testing at least weekly. The median interval from second dose to collection of a positive SARS-CoV-2 specimen was 29 days (interquartile range [IQR] =23–42 days). The median interval between most recent positive NAAT result and last known negative test result was 7 days (IQR =7–14 days). Two-dose vaccination coverage among residents and staff members at facilities with breakthrough infections ranged from 62% to 96% and 18% to 85%, respectively. Among the 15 facilities with breakthrough cases, attack rates2 for unvaccinated and vaccinated residents were 15% (89 of 604) and 0.8% (15 of 1,781), respectively. Among staff members, attack rates for unvaccinated and vaccinated persons were 6% (62 of 992) and 1% (12 of 1135), respectively. Eleven facilities reported a total of 41 confirmed cases within 28 days after initial breakthrough infection at a facility (Table 2). No facility-associated secondary transmission was determined to have occurred because the new cases that occurred after the initial breakthrough infection were not close contacts of the persons with breakthrough infections.

Among the 22 persons with breakthrough infections, 14 (64%; eight residents and six staff members) were asymptomatic (Table 2). Three symptomatic persons (B3, E10, and G13) had mild, nonspecific symptoms; two (E8 and G12) had mild, specific symptoms; and three (A1, D6, and O22) had diagnosed pneumonia. Four residents were hospitalized: two (D6 and O22) for COVID-19–related reasons and two (A1 and D5) for reasons unrelated to COVID-19; one resident (O22) died.

Resident A1 received a diagnosis of pneumonia 9 days after receiving the second COVID-19 vaccine dose and 7 days before receiving a positive SARS-CoV-2 test result (Table 2). Although the timing of the patient’s positive SARS-CoV-2 test result met the definition of a breakthrough infection, the clinical history indicated that the infection likely occurred <14 days after the second dose. Resident D6 was hospitalized for weakness and loss of appetite in association with pneumonia. Resident O22 experienced fatigue and respiratory symptoms and received a diagnosis of pneumonia. This patient had a positive SARS-CoV-2 test result on hospital admission and had concomitant group B β-hemolytic
TABLE 1 Number and percentage of skilled nursing facility residents and staff members with a positive confirmed SARS-CoV-2 test result, by demographic and clinical characteristics and vaccination status — Chicago, Illinois, December 2020–March 2021

| Characteristic                                      | Vaccination status of residents and staff members with SARS-CoV-2 infections, no. (column %) |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------|
|                                                     | Total (n = 627)                                                                                  |
|                                                     | Unvaccinated*(n = 447)                                                                          |
|                                                     | Partially vaccinated*(n = 145)                                                                  |
|                                                     | Vaccinated but not immune* (n = 13)                                                              |
|                                                     | Fully vaccinated with breakthrough infection* (n = 22)                                            |
| Median age (IQR)                                    | 60.0 (43.0–73.0)                                                                                |
|                                                     | 57.0 (39.0–71.0)                                                                                |
|                                                     | 65.0 (50.0–79.0)                                                                                |
|                                                     | 66.0 (58.0–79.0)                                                                                |
|                                                     | 61.5 (41.0–73.0)                                                                                |
| Sex                                                 |                                                                                                 |
| Female                                              | 376 (60.0)                                                                                      |
|                                                     | 265 (59.3)                                                                                      |
|                                                     | 89 (61.4)                                                                                        |
|                                                     | 7 (53.9)                                                                                         |
|                                                     | 15 (68.2)                                                                                       |
| Male                                                | 237 (37.8)                                                                                      |
|                                                     | 168 (37.6)                                                                                      |
|                                                     | 56 (38.6)                                                                                       |
|                                                     | 6 (46.2)                                                                                         |
|                                                     | 7 (31.8)                                                                                         |
| Unknown                                             | 14 (2.2)                                                                                         |
|                                                     | 14 (3.1)                                                                                         |
|                                                     | 0 (–)                                                                                             |
|                                                     | 0 (–)                                                                                             |
| Race/ethnicity                                      |                                                                                                 |
| Hispanic/Latino                                      | 58 (9.3)                                                                                         |
|                                                     | 37 (8.3)                                                                                         |
|                                                     | 16 (11.0)                                                                                       |
|                                                     | 1 (7.7)                                                                                            |
|                                                     | 4 (18.2)                                                                                         |
| Asian, non-Hispanic                                 | 24 (3.8)                                                                                         |
|                                                     | 11 (2.5)                                                                                         |
|                                                     | 9 (6.2)                                                                                            |
|                                                     | 1 (7.7)                                                                                            |
|                                                     | 3 (13.6)                                                                                         |
| Black, non-Hispanic                                 | 252 (40.2)                                                                                       |
|                                                     | 193 (43.2)                                                                                       |
|                                                     | 44 (30.3)                                                                                       |
|                                                     | 7 (53.9)                                                                                         |
|                                                     | 8 (36.4)                                                                                         |
| White, non-Hispanic                                 | 144 (23.0)                                                                                       |
|                                                     | 79 (17.7)                                                                                       |
|                                                     | 55 (37.9)                                                                                       |
|                                                     | 3 (23.1)                                                                                         |
|                                                     | 7 (31.8)                                                                                         |
| Other, non-Hispanic                                 | 16 (2.6)                                                                                         |
|                                                     | 12 (2.7)                                                                                         |
|                                                     | 4 (2.8)                                                                                            |
|                                                     | 0 (–)                                                                                             |
|                                                     | 0 (–)                                                                                             |
| Unknown                                             | 133 (21.2)                                                                                       |
|                                                     | 115 (25.7)                                                                                       |
|                                                     | 17 (11.7)                                                                                       |
|                                                     | 1 (7.7)                                                                                            |
|                                                     | 0 (–)                                                                                             |
| Role                                                |                                                                                                 |
| Resident                                            | 353 (56.3)                                                                                       |
|                                                     | 235 (52.6)                                                                                       |
|                                                     | 97 (66.9)                                                                                       |
|                                                     | 9 (69.2)                                                                                         |
|                                                     | 12 (54.6)                                                                                       |
| Staff member                                         | 274 (43.7)                                                                                       |
|                                                     | 212 (47.4)                                                                                       |
|                                                     | 48 (33.1)                                                                                       |
|                                                     | 4 (30.8)                                                                                         |
|                                                     | 10 (45.5)                                                                                        |
| Symptoms                                            |                                                                                                 |
| Yes                                                 | 92 (14.7)                                                                                         |
|                                                     | 62 (13.9)                                                                                       |
|                                                     | 21 (14.5)                                                                                       |
|                                                     | 1 (7.7)                                                                                           |
|                                                     | 8 (36.4)                                                                                         |
| No                                                  | 34 (5.4)                                                                                         |
|                                                     | 15 (3.4)                                                                                         |
|                                                     | 5 (3.5)                                                                                            |
|                                                     | 0 (–)                                                                                             |
|                                                     | 14 (63.6)                                                                                       |
| Unknown                                             | 501 (79.9)                                                                                       |
|                                                     | 370 (82.8)                                                                                       |
|                                                     | 119 (82.1)                                                                                       |
|                                                     | 12 (92.3)                                                                                       |
|                                                     | 0 (–)                                                                                             |
| Hospitalizations                                    |                                                                                                 |
| Yes                                                 | 123 (19.6)                                                                                       |
|                                                     | 90 (20.1)                                                                                       |
|                                                     | 27 (18.6)                                                                                       |
|                                                     | 2 (15.4)                                                                                         |
|                                                     | 4 (18.2)*                                                                                       |
| No                                                  | 504 (80.4)                                                                                       |
|                                                     | 357 (79.9)                                                                                       |
|                                                     | 118 (81.4)                                                                                       |
|                                                     | 11 (84.6)                                                                                       |
|                                                     | 18 (81.8)                                                                                       |
| Deaths                                              |                                                                                                 |
| Yes                                                 | 21 (3.4)                                                                                         |
|                                                     | 14 (3.1)                                                                                         |
|                                                     | 6 (4.1)                                                                                            |
|                                                     | 0 (–)                                                                                             |
|                                                     | 1 (4.6)                                                                                           |
| No                                                  | 606 (96.7)                                                                                       |
|                                                     | 433 (96.9)                                                                                       |
|                                                     | 139 (95.9)                                                                                       |
|                                                     | 13 (100.0)                                                                                       |
|                                                     | 21 (95.5)                                                                                       |
| Previous positive SARS-CoV-2 result                 |                                                                                                 |
| Yes                                                 | 41 (6.5)                                                                                         |
|                                                     | 22 (4.9)                                                                                         |
|                                                     | 9 (6.2)                                                                                            |
|                                                     | 4 (30.8)                                                                                         |
|                                                     | 6 (27.3)                                                                                         |
| No                                                  | 586 (93.5)                                                                                       |
|                                                     | 425 (95.1)                                                                                       |
|                                                     | 136 (93.8)                                                                                       |
|                                                     | 9 (69.2)                                                                                         |
|                                                     | 16 (72.7)                                                                                        |

Abbreviations: I-NEDSS, Illinois’ National Electronic Disease Surveillance System; IQR, interquartile range.

*Unvaccinated: received no COVID-19 vaccine doses; partially vaccinated: received one dose; vaccinated but not immune: received two doses but <14 days had elapsed since receipt of second dose; and fully vaccinated with breakthrough infection: received two doses and then received a positive SARS-CoV-2 test result ≥14 days after receipt of the second dose.

*Persons with the following races listed in I-NEDSS as American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, other, or multiracial were categorized as non-Hispanic other.

*Data on symptoms were extracted from I-NEDSS for unvaccinated, partially vaccinated, and vaccinated but not immune persons. Most COVID-19 case reports are entered into I-NEDSS through electronic laboratory reporting and provide minimal information (e.g., name, date of birth, and laboratory test and results) needed to meet reporting requirements. Data on symptoms in persons with breakthrough infections were supplemented with details from case investigations, which were not completed for nonbreakthrough cases. Symptom status for many persons with nonbreakthrough infection cases is unknown.

*Two residents were hospitalized for COVID-19–related reasons. Two additional residents were hospitalized for non-COVID-19–related reasons.
streptococcal bacteremia and a *Pseudomonas* urinary tract infection and died 7 days after hospital admission. The death certificate listed complications of COVID-19 infection as primary cause of death; underlying conditions were hypertension, diabetes mellitus, and chronic kidney disease.

Among 12 available specimens from seven patients with breakthrough infections, RT-PCR cycle threshold values were >28, indicating low levels of detectable virus. Six persons with breakthrough infections had a previous positive SARS-CoV-2 test result >90 days before the most recent test, including five persons who had negative test results (range =1–43 tests) between the positive results (Supplementary Figure, https://stacks.cdc.gov/view/cdc/105130) and at least one negative NAAT result <14 days before the postvaccination positive test result. Five persons were asymptomatic during the second infection. Paired specimens for sequence comparison were unavailable.

**DISCUSSION**

Twelve SNF residents and 10 staff members had positive SARS-CoV-2 test results ≥14 days after receiving a second COVID-19 vaccine dose (breakthrough infections). Fourteen (64%) were asymptomatic, available RT-PCR cycle threshold values suggest low viral loads, and no facility-associated secondary transmission was detected. Two residents with breakthrough infections experienced COVID-related hospitalizations, one of whom died because of multiple concurrent infections. Although rare, postvaccination breakthrough infection can occur because COVID-19 vaccines do not offer 100% protection. Early studies suggest that COVID-19 vaccines protect against severe illness and might be effective at preventing infection; however, data on the impact of vaccination on transmission in congregate settings are limited. In addition, some persons whose infections met the case definition of a breakthrough infection might have had persistently positive NAAT results after initial infection; however, most had multiple confirmed negative interim test results. Additional data are needed to differentiate breakthrough infections from sequelae of previous infections and to determine whether persons with breakthrough infections can transmit virus.

The results in this report highlight the importance of COVID-19 vaccination in high-risk congregate settings such as SNFs; most fully vaccinated persons were not infected, did not have COVID-19–like symptoms, and did not have severe illness. Despite the identification of positive NAAT results during the investigation period, breakthrough infections did not lead to secondary transmission at these facilities.

Expanded testing of residents and staff members in these settings in response to clusters or outbreak investigations is also important, regardless of vaccination status, because these persons might have asymptomatic infections. A previous study found that vaccination has an estimated effectiveness of 63% against SARS-CoV-2 infection among SNF residents >14 days after the first dose through 7 days after the second dose. Additional studies are needed to assess the impact of full vaccination in SNFs and to understand how vaccination in settings that include older adults, immunocompromised persons, and persons with known history of SARS-CoV-2 infection compares with clinical trial efficacy data. Whether vaccinated asymptomatic persons can transmit SARS-CoV-2 is also
| Facility | Patient | Sex, age (years) | Role | Symptoms | Hospitalized | Death | No. of days between second vaccine dose and positive specimen collection | Ct value<sup>b</sup> | Previous positive SARS-CoV-2 test result | No. of days between last negative SARS-CoV-2 test result and postvaccination positive test | No. of facility cases occurring after breakthrough infection<sup>g</sup> | No. of cases considered close contacts<sup>d</sup> |
|----------|---------|-----------------|------|----------|--------------|-------|-----------------------------------------------------------------|-----------------|----------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| A        | 1       | F, 75           | Resident | Pneumonia, seizure | Yes, not COVID-19 related<sup>e</sup> | No | 16 | - | No | - | 23 | 3 | 0 |
| B        | 2       | F, 63           | Staff | None | No | No | 21 | - | No | - | 6 | 3 | 0 |
|          | 3       | F, 36           | Staff | HA, fatigue | No | No | 29 | - | No | - | 7 | 2 | 0 |
| C        | 4       | F, 83           | Resident | None | No | No | 18 | 26.2 | No | - | 7 | 2 | 0 |
| D        | 5       | M, 64           | Resident | None | Yes, not COVID-19 related<sup>e</sup> | No | 15 | - | Yes | 96 | 106 | 2 | 0 |
|          | 6       | M, 73           | Resident | Pneumonia, weakness | Yes, COVID-19 related<sup>d</sup> | No | 21 | - | No | - | 112 | 2 | 0 |
|          | 7       | F, 70           | Resident | None | No | No | 42 | 28.8 | No | - | 7 | 4 | 0 |
| E        | 8       | F, 82           | Resident | Fatigue, cough | No | No | 19 | 26.9 | No | - | 29 | 9 | 0 |
|          | 9       | F, 95           | Resident | None | No | No | 28 | - | Yes | 303 | 9 | 5 | 0 |
|          | 10      | F, 29           | Staff | HA | No | No | 34 | 50.0<sup>h</sup> | No | - | 7 | 1 | 0 |
| F        | 11      | F, 46           | Resident | None | No | No | 29 | - | Yes | 112 | 8 | 0 | NA |
| G        | 12      | F, 36           | Staff | Chills, myalgia, HA, sore throat, fatigue, cough, loss of taste or smell | No | No | 27 | 29.9 | No | - | 4 | 2 | 0 |
|          | 13      | F, 46           | Staff | Sore throat, nausea, diarrhea | No | No | 51 | 27.7 | No | - | 10 | 2 | 0 |
| H        | 14      | M, 41           | Staff | None | No | No | 29 | 32.6 | Yes | 214 | 7 | 1 | 0 |
| I        | 15      | F, 37           | Staff | None | No | No | 39 | 28.6 | No | - | 5 | 1 | 0 |

(Continues)
| Facility | Patient | Sex, age (years) | Role | Symptoms | Hospitalized | Death | No. of days between second vaccine dose and positive specimen collection | Ct value<sup>b</sup> | Previous positive SARS-CoV-2 test result | No. of days between initial and most recent positive test result | No. of days between last negative SARS-CoV-2 test result and postvaccination positive test | No. of facility cases occurring after breakthrough infection<sup>c</sup> | No. of cases considered close contacts<sup>d</sup> |
|----------|---------|-----------------|------|----------|--------------|-------|-------------------------------------------------|----------------|---------------------------------|-----------------------------|-------------------------------------------------|---------------------------------|---------------------------------|
| J        | 16      | M, 60           | Resident | None | No | No | 31 | 38.5 | No | 7 | 1 | 0 |
|          | 17      | M, 26           | Staff | None | No | No | 53 | – | No | 7 | 14 | 1 | 0 |
| K        | 18      | F, 57           | Staff | None | No | No | 27 | 28.3 | No | 7 | 7 | 0 |
| L        | 19      | F, 49           | Staff | None | No | No | 42 | 16.9 | No | 7 | 220 | 0 | NA |
| M        | 20      | F, 77           | Resident | None | No | No | 45 | 20.5 | No | 7 | 0 | NA |
| N        | 21      | F, 70           | Resident | None | No | No | 56 | – | Yes | 137 | 7 | 4 | 0 |
| O        | 22      | M, 66           | Resident | Pneumonia, fatigue, cough, SOB, difficulty breathing | Yes, COVID-19 related<sup>1</sup> | Yes<sup>1</sup> | 46 | – | Yes | 152 | 13 | 0 | NA |

Abbreviations: Ct, cycle threshold; F, female; HA, headache; M, male; NA, not applicable; NAAT, nucleic acid amplification test; SOB = shortness of breath.

<sup>a</sup>Receipt of a positive SARS-CoV-2 NAAT (e.g., reverse transcription–polymerase chain reaction) or antigen test result from a respiratory specimen collected ≥14 days after completing the two-dose COVID-19 vaccination series.

<sup>b</sup>Missing Ct values are for specimens that were discarded by the laboratory and unavailable for sequencing.

<sup>c</sup>Cases identified within a 28-day monitoring window from the date of specimen collection for the breakthrough infection. For facilities with multiple breakthrough infections, 28-day monitoring windows might overlap, and new facility cases might be listed multiple times.

<sup>d</sup>When a new case in a facility was identified, infection prevention specialists determined whether the person with the case met criteria to be considered a close contact of the person with the breakthrough infection. Data in this column represent the number of cases in persons that met the definition of a close contact and occurred after identification of the breakthrough infection as of April 12, 2021.

<sup>e</sup>Resident A1 had a positive SARS-CoV-2 test result 16 days after receiving the second dose of COVID-19 vaccine, which was an incidental finding when admitted to the hospital for new onset of seizures. The positive result might have been related to an episode of pneumonia diagnosed 9 days after the second dose. COVID-19 testing was not associated with compatible symptoms, and this resident was included because the resident’s case met the laboratory-based breakthrough infection definition. This resident likely did not experience a breakthrough infection because previous pneumonia onset is suggestive of SARS-CoV-2 infection before full immunization.

<sup>f</sup>Resident D5 had a positive preprocedural SARS-CoV-2 test result and was subsequently hospitalized for non-COVID-19–related reasons, including multiple falls and a bloodstream infection related to a midline catheter.

<sup>g</sup>Resident D6 was hospitalized for COVID-19–related reasons because of weakness and loss of appetite in association with pneumonia diagnosed at hospital admission.

<sup>h</sup>Based on the symptomatic disease case definition outlined by the Council of State and Territorial Epidemiologists, patient E10 had nonspecific COVID-19 symptoms. Previous testing history was examined using the Illinois’ National Electronic Disease Surveillance System. No known previous positive SARS-CoV-2 were identified for this patient.

<sup>i</sup>Resident O22 was hospitalized for COVID-19–related reasons because of fatigue, cough, SOB, and difficulty breathing. SARS-CoV-2 test result was positive, and resident received a diagnosis of pneumonia requiring hospital admission and intubation in the intensive care unit for hypoxic respiratory failure. Concomitant infections including group B streptococcal bacteremia and Pseudomonas urinary tract infection were also identified. The resident died 7 days after hospital admission.
Vaccine effectiveness estimates for prevention of SARS-CoV-2 infection and COVID-19 were not calculated because CDPH does not have access to SNF electronic medical records, limiting the ability to obtain individual-level data from facilities on all residents and staff members and to calculate person-time among vaccinated and unvaccinated persons who were not infected. Facilities did not have the capacity to provide line lists and vaccination information for noninfected residents and staff members.

The findings in this report are subject to at least four limitations. First, confirming whether patients with a breakthrough infection and a previous positive SARS-CoV-2 test result had a true reinfection or represented persons with prolonged shedding from previous infection was not possible. Intermittent prolonged SARS-CoV-2 shedding is well described. In addition to two SARS-CoV-2 tests ≥90 days apart, paired respiratory specimens are needed so that their genetic sequences can be compared. Data such as epidemiologic links to confirmed cases and clinical course can provide supporting evidence for reinfection but do not definitively identify reinfection events. Second, vaccination data in this report are limited to Chicago residents and persons vaccinated in Chicago; data were unavailable for staff members who were not Chicago residents and were vaccinated outside Chicago. Third, data entry errors or delayed surveillance reporting might prevent record matching, leading to an underestimate of breakthrough infections. Finally, although some specimens were submitted for genotyping to evaluate possible variant strains, results are pending and not yet available.

SNFs should continue to follow recommended infection prevention and control practices, including work restrictions, isolation of persons with confirmed cases, quarantine of residents who have had close contact with persons with confirmed cases, routine and outbreak testing of residents and staff members, and use of personal protective equipment, regardless of vaccination status. Maintaining high vaccination coverage among residents and staff members is also important to reduce opportunities for transmission within facilities and exposure among persons who might not have achieved protective immunity after vaccination.

ACKNOWLEDGMENTS
Allison Arwady, Isaac Ghinai, Marielle Fricchione; Massimo Pacilli, Hira Adil, Shane Zelencik, Adebola Hassan, Winter Viverette, Amy Hanson, Daniel Galanto, Franziska Andonopoulos, Shemenia Ladd; residents and staff members of all Chicago-based skilled nursing facilities, including the administrative, medical, nursing, and infection prevention staff at the facilities with breakthrough infections.

CONFLICT OF INTEREST
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

ENDNOTES

1 A public-private partnership among CDC; CVS Pharmacy; Managed Health Care Associates, Inc.; and Walgreens to provide on-site COVID-19 vaccination of residents and staff members at enrolled long-term care facilities, including SNFs. https://www.cdc.gov/vaccines/covid-19/long-term-care/pharmacy-partnerships.html
2 CDPH advises facilities to routinely test residents at least monthly. Staff members were also required to receive testing routinely, with frequency determined based on community positivity rate and other metrics of interest. Staff members at all Chicago-based SNFs were tested at least twice weekly (until February 4, 2021), then weekly (during February 4–March 18, 2021), then biweekly (from March 18, 2021 through the end of investigation period). In response to a facility outbreak (i.e., a resident or staff member with a case within the past 14 days), all staff members and residents (excluding those who received a positive SARS-CoV-2 test <90 days previously) are required to receive testing at least every 3–7 days until no new cases occur for at least 14 days. At the time a breakthrough infection was identified, frequency of resident testing at the 15 SNFs ranged from monthly to twice per week; frequency of staff member testing ranged from weekly to twice weekly.
3 First round vaccination clinics occurred during December 28, 2020–January 18, 2021. Persons were included in the study if infection occurred between the first clinic date at their respective facility and March 31, 2021. Moderna COVID-19 vaccination was exclusively administered at Chicago-based SNFs through the federal PPP. Six residents and two staff members received Pfizer-BioNTech COVID-19 vaccine through Chicago-based vaccine providers not participating in the federal PPP or facilities outside the city of Chicago.
4 CDC breakthrough infection guidance: https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html. Residents and staff members were excluded from the investigation if they had received 1) a positive SARS-CoV-2 test result from December 28 through the date of their facility’s first vaccination clinic or 2) a known initial positive SARS-CoV-2 test result <90 days before their most recent SARS-CoV-2 test result.
5 For residents, close contact was defined as being within 6 ft of a person for ≥15 minutes over a 24-hour period, regardless of personal protective equipment used. For staff members, close contact was defined as being within 6 ft of a person for ≥15 minutes over a 24-hour period when one or both persons were unmasked.
6 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
7 To calculate attack rates, residents and staff members who had never received COVID-19 vaccine (i.e., unvaccinated persons) and those who had received one COVID-19 vaccine dose of a two-dose series (i.e., partially vaccinated persons) were categorized as unvaccinated. Residents and staff members who had received two COVID-19 vaccine doses of a two-dose series and ≤14 days or ≥14 days had elapsed (i.e., vaccinated but not immune and fully vaccinated persons, respectively) were categorized as vaccinated. Aggregate vaccination data were only available for residents and staff members who received two doses of COVID-19 vaccine and did not have a SARS-CoV-2 infection. In the denominator, differentiation between persons who received two doses <14 days or ≥14 days was not possible.
8 Cases identified within a 28-day monitoring window from the date of specimen collection for the breakthrough infection. For facilities with multiple breakthrough infections, 28-day monitoring windows might overlap, and new facility cases might be listed multiple times. As of April 12, 2021, nine of the 41 cases were breakthrough infections; seven of which are listed (see Table 2) and occurred during the investigation period.
Symptoms were categorized as nonspecific, mild, or moderate based on the National Notifiable Diseases Surveillance System and Council of State and Territorial Epidemiologists definition of symptomatic COVID-19. https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/

https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homes-testing.html

https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-after-vaccination.html

https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html

https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html

REFERENCES

1. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495-500.

2. Baden LR, El Sahly HM, Essink B, et al.; COVE Study Group. Efficacy and safety of the mRNA-123 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-416.

3. Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.

4. Bagchi S, Mak J, Li Q, et al. Rates of COVID-19 among residents and staff members in nursing homes—United States, May 25–November 22, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:52-55.

5. Centers for Medicare & Medicaid Services. COVID-19 nursing home data. Baltimore, MD: US Department of Health and Human Services, Centers for Medicare & Medicaid Services; 2020. https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg

6. Dooling K, McClung N, Chamberland M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine—United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1857-1859.

7. Gharpure R, Guo A, Bishnoi CK, et al. Early COVID-19 first-dose vaccination coverage among residents and staff members of skilled nursing facilities participating in the Pharmacy Partnership for Long-Term Care Program—United States, December 2020–January 2021. MMWR Morb Mortal Wkly Rep. 2021;70:178-182.

8. Britton A, Jacobs Slifka KM, Edens C, et al. Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021;70:396-401.

9. AlJishi JM, Al-Tawfiq JA. Intermittent viral shedding in respiratory samples of patients with SARS-CoV-2: observational analysis with infection control implications. J Hosp Infect. 2021;107:98-100.

How to cite this article: Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members — Chicago, Illinois, December 2020–March 2021. Am J Transplant. 2021;21:2290–2297. https://doi.org/10.1111/ajt.16634